Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication

Neither treatment duration provides acceptable eradication rate in Korea

Byeong Gwan Kim, Dong Ho Lee, Byong Duk Ye, Kwang Hyuck Lee, Beung Wook Kim, Sang Gyun Kim, Sang Woo Kim, Sung Kook Kim, Jae J. Kim, Hak Yang Kim, Jong Jae Park, Chang Young Park, Gwang Ho Baik, Yong Chan Lee, Jun Haeng Lee, Jin Hyug Lee, Hoon-Jai Chun, Ki Baik Hahm, Su Jin Hong, Sang Woo Lee & 1 others Hyun Chae Jung

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background and Aims: Although triple combination therapy containing a proton pump inhibitor (PPI) and two antibiotics is considered as a standard regimen for the first-line anti-Helicobacter pylori treatment, there are still debates on the ideal duration of treatment. The aim of this study was to compare the efficacies of 7-day and 14-day PPI-containing triple therapy. Materials and Methods: This study was performed in a randomized, multicenter, prospective manner. After upper gastrointestinal endoscopy, H. pylori-infected patients with a gastric ulcer and/or a duodenal ulcer were randomly assigned to a PAC7 group (omeprazole 20 mg or equivalent dose of other PPIs, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days) or to a PAC14 group (the same regimen as the PAC7 group but for 14 days). H. pylori status was evaluated by 13C urea breath test 5 weeks after anti-ulcer treatment completion. Results: A total of 598 patients were enrolled; 337 were randomized to the PAC7 group and 261 to the PAC14 group. The two groups were comparable in terms of baseline characteristics. The eradication rates of the PAC7 group were not inferior to those of the PAC14 group in both intention-to-treat analysis (71.2% vs. 75.5%) and per-protocol analysis (83.6% vs. 86.6%). Incidences of adverse events were comparable. Conclusions: Although the 7-day PPI-containing triple anti-H. pylori therapy is not inferior to the 14-day therapy, neither treatment duration provides acceptable eradication rate reaching 90% in per-protocol analysis. New combination regimen with higher efficacy should be developed as a first-line eradication therapy for H. pylori in Korea.

Original languageEnglish
Pages (from-to)31-35
Number of pages5
JournalHelicobacter
Volume12
Issue number1
DOIs
Publication statusPublished - 2007 Feb 1

Fingerprint

Proton Pump Inhibitors
Korea
Helicobacter pylori
Therapeutics
Intention to Treat Analysis
Breath Tests
Gastrointestinal Endoscopy
Clarithromycin
Omeprazole
Amoxicillin
Stomach Ulcer
Duodenal Ulcer
Ulcer
Urea
Anti-Bacterial Agents
Incidence

Keywords

  • Eradication rate
  • First line treatment
  • Helicobacter pylori

ASJC Scopus subject areas

  • Gastroenterology
  • Microbiology

Cite this

Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication : Neither treatment duration provides acceptable eradication rate in Korea. / Kim, Byeong Gwan; Lee, Dong Ho; Ye, Byong Duk; Lee, Kwang Hyuck; Kim, Beung Wook; Kim, Sang Gyun; Kim, Sang Woo; Kim, Sung Kook; Kim, Jae J.; Kim, Hak Yang; Park, Jong Jae; Park, Chang Young; Baik, Gwang Ho; Lee, Yong Chan; Lee, Jun Haeng; Lee, Jin Hyug; Chun, Hoon-Jai; Hahm, Ki Baik; Hong, Su Jin; Lee, Sang Woo; Jung, Hyun Chae.

In: Helicobacter, Vol. 12, No. 1, 01.02.2007, p. 31-35.

Research output: Contribution to journalArticle

Kim, BG, Lee, DH, Ye, BD, Lee, KH, Kim, BW, Kim, SG, Kim, SW, Kim, SK, Kim, JJ, Kim, HY, Park, JJ, Park, CY, Baik, GH, Lee, YC, Lee, JH, Lee, JH, Chun, H-J, Hahm, KB, Hong, SJ, Lee, SW & Jung, HC 2007, 'Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: Neither treatment duration provides acceptable eradication rate in Korea', Helicobacter, vol. 12, no. 1, pp. 31-35. https://doi.org/10.1111/j.1523-5378.2007.00468.x
Kim, Byeong Gwan ; Lee, Dong Ho ; Ye, Byong Duk ; Lee, Kwang Hyuck ; Kim, Beung Wook ; Kim, Sang Gyun ; Kim, Sang Woo ; Kim, Sung Kook ; Kim, Jae J. ; Kim, Hak Yang ; Park, Jong Jae ; Park, Chang Young ; Baik, Gwang Ho ; Lee, Yong Chan ; Lee, Jun Haeng ; Lee, Jin Hyug ; Chun, Hoon-Jai ; Hahm, Ki Baik ; Hong, Su Jin ; Lee, Sang Woo ; Jung, Hyun Chae. / Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication : Neither treatment duration provides acceptable eradication rate in Korea. In: Helicobacter. 2007 ; Vol. 12, No. 1. pp. 31-35.
@article{328f535194c44cd7a86089f97d8735d9,
title = "Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: Neither treatment duration provides acceptable eradication rate in Korea",
abstract = "Background and Aims: Although triple combination therapy containing a proton pump inhibitor (PPI) and two antibiotics is considered as a standard regimen for the first-line anti-Helicobacter pylori treatment, there are still debates on the ideal duration of treatment. The aim of this study was to compare the efficacies of 7-day and 14-day PPI-containing triple therapy. Materials and Methods: This study was performed in a randomized, multicenter, prospective manner. After upper gastrointestinal endoscopy, H. pylori-infected patients with a gastric ulcer and/or a duodenal ulcer were randomly assigned to a PAC7 group (omeprazole 20 mg or equivalent dose of other PPIs, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days) or to a PAC14 group (the same regimen as the PAC7 group but for 14 days). H. pylori status was evaluated by 13C urea breath test 5 weeks after anti-ulcer treatment completion. Results: A total of 598 patients were enrolled; 337 were randomized to the PAC7 group and 261 to the PAC14 group. The two groups were comparable in terms of baseline characteristics. The eradication rates of the PAC7 group were not inferior to those of the PAC14 group in both intention-to-treat analysis (71.2{\%} vs. 75.5{\%}) and per-protocol analysis (83.6{\%} vs. 86.6{\%}). Incidences of adverse events were comparable. Conclusions: Although the 7-day PPI-containing triple anti-H. pylori therapy is not inferior to the 14-day therapy, neither treatment duration provides acceptable eradication rate reaching 90{\%} in per-protocol analysis. New combination regimen with higher efficacy should be developed as a first-line eradication therapy for H. pylori in Korea.",
keywords = "Eradication rate, First line treatment, Helicobacter pylori",
author = "Kim, {Byeong Gwan} and Lee, {Dong Ho} and Ye, {Byong Duk} and Lee, {Kwang Hyuck} and Kim, {Beung Wook} and Kim, {Sang Gyun} and Kim, {Sang Woo} and Kim, {Sung Kook} and Kim, {Jae J.} and Kim, {Hak Yang} and Park, {Jong Jae} and Park, {Chang Young} and Baik, {Gwang Ho} and Lee, {Yong Chan} and Lee, {Jun Haeng} and Lee, {Jin Hyug} and Hoon-Jai Chun and Hahm, {Ki Baik} and Hong, {Su Jin} and Lee, {Sang Woo} and Jung, {Hyun Chae}",
year = "2007",
month = "2",
day = "1",
doi = "10.1111/j.1523-5378.2007.00468.x",
language = "English",
volume = "12",
pages = "31--35",
journal = "Helicobacter",
issn = "1083-4389",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication

T2 - Neither treatment duration provides acceptable eradication rate in Korea

AU - Kim, Byeong Gwan

AU - Lee, Dong Ho

AU - Ye, Byong Duk

AU - Lee, Kwang Hyuck

AU - Kim, Beung Wook

AU - Kim, Sang Gyun

AU - Kim, Sang Woo

AU - Kim, Sung Kook

AU - Kim, Jae J.

AU - Kim, Hak Yang

AU - Park, Jong Jae

AU - Park, Chang Young

AU - Baik, Gwang Ho

AU - Lee, Yong Chan

AU - Lee, Jun Haeng

AU - Lee, Jin Hyug

AU - Chun, Hoon-Jai

AU - Hahm, Ki Baik

AU - Hong, Su Jin

AU - Lee, Sang Woo

AU - Jung, Hyun Chae

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Background and Aims: Although triple combination therapy containing a proton pump inhibitor (PPI) and two antibiotics is considered as a standard regimen for the first-line anti-Helicobacter pylori treatment, there are still debates on the ideal duration of treatment. The aim of this study was to compare the efficacies of 7-day and 14-day PPI-containing triple therapy. Materials and Methods: This study was performed in a randomized, multicenter, prospective manner. After upper gastrointestinal endoscopy, H. pylori-infected patients with a gastric ulcer and/or a duodenal ulcer were randomly assigned to a PAC7 group (omeprazole 20 mg or equivalent dose of other PPIs, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days) or to a PAC14 group (the same regimen as the PAC7 group but for 14 days). H. pylori status was evaluated by 13C urea breath test 5 weeks after anti-ulcer treatment completion. Results: A total of 598 patients were enrolled; 337 were randomized to the PAC7 group and 261 to the PAC14 group. The two groups were comparable in terms of baseline characteristics. The eradication rates of the PAC7 group were not inferior to those of the PAC14 group in both intention-to-treat analysis (71.2% vs. 75.5%) and per-protocol analysis (83.6% vs. 86.6%). Incidences of adverse events were comparable. Conclusions: Although the 7-day PPI-containing triple anti-H. pylori therapy is not inferior to the 14-day therapy, neither treatment duration provides acceptable eradication rate reaching 90% in per-protocol analysis. New combination regimen with higher efficacy should be developed as a first-line eradication therapy for H. pylori in Korea.

AB - Background and Aims: Although triple combination therapy containing a proton pump inhibitor (PPI) and two antibiotics is considered as a standard regimen for the first-line anti-Helicobacter pylori treatment, there are still debates on the ideal duration of treatment. The aim of this study was to compare the efficacies of 7-day and 14-day PPI-containing triple therapy. Materials and Methods: This study was performed in a randomized, multicenter, prospective manner. After upper gastrointestinal endoscopy, H. pylori-infected patients with a gastric ulcer and/or a duodenal ulcer were randomly assigned to a PAC7 group (omeprazole 20 mg or equivalent dose of other PPIs, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days) or to a PAC14 group (the same regimen as the PAC7 group but for 14 days). H. pylori status was evaluated by 13C urea breath test 5 weeks after anti-ulcer treatment completion. Results: A total of 598 patients were enrolled; 337 were randomized to the PAC7 group and 261 to the PAC14 group. The two groups were comparable in terms of baseline characteristics. The eradication rates of the PAC7 group were not inferior to those of the PAC14 group in both intention-to-treat analysis (71.2% vs. 75.5%) and per-protocol analysis (83.6% vs. 86.6%). Incidences of adverse events were comparable. Conclusions: Although the 7-day PPI-containing triple anti-H. pylori therapy is not inferior to the 14-day therapy, neither treatment duration provides acceptable eradication rate reaching 90% in per-protocol analysis. New combination regimen with higher efficacy should be developed as a first-line eradication therapy for H. pylori in Korea.

KW - Eradication rate

KW - First line treatment

KW - Helicobacter pylori

UR - http://www.scopus.com/inward/record.url?scp=33846247393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846247393&partnerID=8YFLogxK

U2 - 10.1111/j.1523-5378.2007.00468.x

DO - 10.1111/j.1523-5378.2007.00468.x

M3 - Article

VL - 12

SP - 31

EP - 35

JO - Helicobacter

JF - Helicobacter

SN - 1083-4389

IS - 1

ER -